{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:21:53Z","timestamp":1790216513211,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ijrobp.2022.09.052","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T06:38:10Z","timestamp":1663051090000},"page":"202-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"title":["Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced\/Unresectable Hepatocellular Carcinoma"],"prefix":"10.1016","volume":"115","author":[{"given":"Aditya","family":"Juloori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan R.","family":"Katipally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Lemons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renuka","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared R.","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Pitroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fauzia","family":"Arif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Yi","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley L.","family":"Liauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2022.09.052_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0002","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0003","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0004","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3748\/wjg.v19.i3.366","article-title":"Role of surgical resection for multiple hepatocellular carcinomas","volume":"19","author":"Choi","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0005","doi-asserted-by":"crossref","DOI":"10.1177\/1533033818790217","article-title":"Stereotactic body radiation therapy for hepatocellular carcinoma: Current trends and controversies","volume":"17","author":"Schaub","year":"2018","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0006","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2012.44.1659","article-title":"Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma","volume":"31","author":"Bujold","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0007","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/j.ijrobp.2011.04.011","article-title":"Stereotactic body radiotherapy for primary hepatocellular carcinoma","volume":"81","author":"Andolino","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0008","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3109\/0284186X.2013.820342","article-title":"Stereotactic body radiotherapy for small hepatocellular carcinoma: A retrospective outcome analysis in 185 patients","volume":"53","author":"Sanuki","year":"2014","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0009","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0010","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0011","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0012","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0013","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0014","doi-asserted-by":"crossref","first-page":"E3025","DOI":"10.3390\/cancers12103025","article-title":"Immune checkpoint inhibitors in hepatocellular carcinoma: Current status and novel perspectives","volume":"12","author":"Federico","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0015","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev-med-042220-021121","article-title":"Hepatocellular carcinoma immunotherapy","volume":"73","author":"Sperandio","year":"2022","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0016","doi-asserted-by":"crossref","first-page":"567","DOI":"10.6004\/jnccn.2021.7037","article-title":"Integration of systemic and liver-directed therapies for locally advanced hepatocellular cancer: Harnessing potential synergy for new therapeutic horizons","volume":"19","author":"Bent","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.568759","article-title":"Combinational immunotherapy for hepatocellular carcinoma: Radiotherapy, immune checkpoint blockade and beyond","volume":"11","author":"Lee","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0018","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2017.76.2229","article-title":"Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors","volume":"36","author":"Luke","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0019","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0020","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2468-1253(21)00427-1","article-title":"Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: A randomised, open-label, phase 2 trial","volume":"7","author":"Kaseb","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"15 suppl","key":"10.1016\/j.ijrobp.2022.09.052_bib0021","article-title":"Results of KEYNOTE-240: Phase 3 study of pembrolizumab (pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC)","volume":"37","author":"Finn","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0022","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: The CheckMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"issue":"4 suppl","key":"10.1016\/j.ijrobp.2022.09.052_bib0023","article-title":"Nivolumab (NIVO)\u00a0+\u00a0ipilimumab (IPI)\u00a0+\u00a0cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040","volume":"38","author":"Yau","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0024","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jhep.2020.08.010","article-title":"Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma","volume":"74","author":"Kim","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0025","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1158\/1078-0432.CCR-20-1790","article-title":"Improved survival associated with local tumor response following multisite radiotherapy and pembrolizumab: Secondary analysis of a phase 1 trial","volume":"26","author":"Luke","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0026","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0027","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0028","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0029","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/hep.26731","article-title":"Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma","volume":"59","author":"Flecken","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0030","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: a beneficial liaison?","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0031","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3389\/fonc.2019.01157","article-title":"Combined stereotactic body radiotherapy and checkpoint inhibition in unresectable hepatocellular carcinoma: A potential synergistic treatment strategy","volume":"9","author":"Chiang","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0032","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/j.ijrobp.2021.07.352","article-title":"Combined stereotactic body radiotherapy and immunotherapy (SBRT-IO) vs. TACE in locally advanced hepatocellular carcinoma (HCC): Propensity score matching analysis","volume":"111","author":"Chiang","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0033","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jtho.2021.08.019","article-title":"A Phase 1 trial of concurrent or sequential ipilimumab, nivolumab, and stereotactic body radiotherapy in patients with stage IV NSCLC study","volume":"17","author":"Bestvina","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2022.09.052_bib0034","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: The LEGACY study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301622033442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301622033442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T10:03:44Z","timestamp":1759745024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301622033442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0360301622033442"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2022.09.052","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced\/Unresectable Hepatocellular Carcinoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2022.09.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}